R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Total Liabilities & Equity
ÂĄ2.1B
CAGR 3-Years
58%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Liabilities & Equity
ÂĄ74.4B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Liabilities & Equity
ÂĄ23B
CAGR 3-Years
9%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Liabilities & Equity
ÂĄ56.1B
CAGR 3-Years
9%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Liabilities & Equity
ÂĄ30.4B
CAGR 3-Years
11%
CAGR 5-Years
37%
CAGR 10-Years
38%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Liabilities & Equity
ÂĄ6.7B
CAGR 3-Years
155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.1B CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Total Liabilities & Equity amounts to 2.1B CNY.

What is R&G PharmaStudies Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
58%

Over the last year, the Total Liabilities & Equity growth was 10%. The average annual Total Liabilities & Equity growth rates for R&G PharmaStudies Co Ltd have been 58% over the past three years .

Back to Top